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Results: Sera from 43 consecutive limited cutaneous (lc) SSc
subjects, 44 early (<3 years from disease onset) diffuse cutaneous
(dc) SSc patients and 20 age, gender and ethnicity matched healthy
controls were analysed. There were no differences between lcSSc and
dcSSc patients in terms of gender or ethnicity, age at disease onset or
sample collection. As expected the lcSSc subjects more often had
overlap syndromes compared to the dcSSc ones (30% v 11%,
p<0.001), and had higher frequency of anti-centromere antibodies
(49% v 2%, p<0.001), while anti-RNA polymerase III antibodies were
found only in the dcSSc cohort (32% v 0%, p<0.001). The meanSD
disease duration at sample collection was significantly longer for the
lcSSc cohort (13283 months) compared to 2212 for dcSSc
cohort. There were no differences between the two subsets in
frequency of clinically significant internal organ disease. MMP7
levels varied between 1.1 and 84.5 ng/mL (meanSD 8.8 8.5,
median 6.7 ng/mL) while MMP9 levels were measured between 54
and 5405 ng/mL (meanSD 651.9562, median 548.6 ng/mL). There
was no correlation between MMP7 and MMP9 levels.
We found no gender or ethnicity differences in the levels of MMP7
and MMP9. Compared to healthy controls SSc patients had altered
levels of both MMP7 and MMP9 - mean MMP7 level was 10.2 ng/mL
for dcSSc, 8.9 ng/mL for lcSSc and 4.6 ng/mL for control groups
(p<0.001) while mean MMP9 level was 892 ng/mL for dcSSc, 460.8 ng/
mL for lcSSc and 607.2 ng/mL for controls (p< 0.001). The only
significant association with autoantibodies we observed was for anti-
topoisomerase I antibody (ATA) positive patients who had higher
MMP7 levels (mean 14.3 ng/mL) compared to ATA negative subjects
(8.23 ng/mL), p¼0.049. MMP7 levels were also higher in subjects with
clinically significant (cs) PF (13.8 ng/mL) compared to those without
(8.13 ng/mL, p¼ 0.017) and in subjects who developed renal crisis
(16.5 ng/mL) compared to those who did not (8.8 ng/mL, p¼0.016).
There was no association of MMP7 and MMP9 levels with pulmonary
hypertension, cardiac scleroderma or severe digital vasculopathy. We
also found no correlation between mRss and MMP7 or MMP9 levels.
Conclusions: Both MMP7 and MMP9 levels were higher in dcSSc
subjects compared to lcSSc subjects or controls. Higher MMP7 levels
were also associated with ATA positivity, development of csPF and
SRC. Both MMP7 and MMP9 may have potential as biomarkers in SSc
and further study is warranted.
Disclosure statement: The authors have declared no conflicts of
interest.
243. ELEVATED IL-6 LEVELS ASSOCIATE WITH POOR
CLINICAL OUTCOME AND MAY PROMOTE FIBROSIS
IN EARLY dcSSc
Korsa Khan1, Chris Denton1, Shiwen Xu1 and Voon Ong1
1Centre for Rheumatology and Connective Tissue Diseases, London,
United Kingdom
Background: We previously showed that thrombocytosis may identify
a subgroup of diffuse SSc with increased IL-6 and high modified
Rodnan skin score (mRSS). We assessed the predictive value of high
IL-6 in these patients and its role in driving fibrosis in SSc.
Methods: IL-6 levels were assessed with immunohistochemistry and
Western blot analysis. Skin biopsies from patients with early dcSSc
and thrombocytosis(n¼ 10,mean platelet:472x109/L,disease duration,
MeanSEM:35 9.5 months),established dcSSc(n¼8,mean plate-
let:293x109/L, disease duration:12822) and controls(n¼ 12) were
used. IL-6 levels were measured in the supernatant from cultured SSc
fibroblasts and the effect of anti-IL6 receptor antibody on collagen
production was examined in normal fibroblasts stimulated with IL-6.
To investigate the link between IL-6 levels and clinical outcome
serum IL-6(in pg/ml) from 39 patients with dcSSc (74% female) was
quantified by ELISA. The dcSSc cases were categorised into high
IL-6(10 pg/ml) and low IL-6 cohorts. Association between IL-6 levels
and mRSS at 36months from disease onset was determined by
Pearson’s correlation. Mean difference of mRSS between the two
cohorts of IL-6 levels over the 36-month period was compared by
Student t-test. Difference in survival between cohorts was examined
using Kaplan-Meier methods.
Results: There was greater dermal IL-6 expression in patients with
early dcSSc than other subgroups. Strong immunostaining for IL-6
was associated with dermal fibroblasts, vascular structures and
mononuclear inflammatory infiltrate in 80% of patients with early
dcSSc. Moderate vascular expression for IL-6 was observed in 33% of
healthy controls. Similar expression pattern was observed in 25%
patients with established dcSSc with weak staining for IL-6 in dermal
fibroblasts and inflammatory infiltrates.
IL-6 was elevated in the supernatant from cultured SSc fibroblasts
(n¼ 3) by 17-fold (Densitometric Image Unit, DIU p<0.05). In addition,
collagen production was upregulated by 7-fold in SSc fibroblasts and
similar induction by recombinant IL-6(20 ng/ml) was observed in
normal fibroblasts (17.94þ3.41 vs 2.18þ 1.85 DIU control, p<0.05).
This was partially abrogated with neutralising antibody against IL-6
receptor (4.26þ2.07 DIU, p<0.05).
Serum IL-6 level at presentation positively correlated with mRSS
at 36 months follow-up in a subgroup of dcSSc cases (r¼0.81,
p<0.01, n¼16). There was a significant difference in mean mRSS
between the two groups with differential IL-6 expression (10.9, 95%
Confidence interval, 3.8, 18.2, p<0.01). Kaplan-Meier analysis
showed that the 5-year survival was 93% and 81% in the group with
low and high IL-6 levels respectively (p¼0.02, log rank test).
Conclusions: This data confirms upregulation of IL-6 in some cases of
early dcSSc and support the potential role of IL-6 as a surrogate
marker for clinical outcome in SSc. Our study also suggests that IL-6
may a logical target for therapy in this subset of patients.
Disclosure statement: The authors have declared no conflicts of
interest.
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DOPPLER ULTRASOUND OF SACROILICAC JOINTS AGAINTS
PHYSICAL EXAMINATION AS GOLD STANDARD
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Leticia Lojo-Oliveira1 and Emilio Martin-Mola1
1Rheumatology, La Paz University Hospital, Madrid, Spain
Background: Sacroiliac joints (SJ) involvement is a distinctive and
charasteristic feature of Spondyloarthritis (SpA) and x-ray is the test
routinely used to make a diagnosis. However, x-ray reveals late
structural damage but cannot detect active inflammation. The
objective of this study was to assess the validity of Doppler ultrasound
in SJ.
Methods: Prospective blinded and controlled study of SJ, in which
three populations were compared. We studied 106 consecutive cases,
who were divided into three groups: a) 53 patients diagnosed with
SpA who had inflammatory lumbar and gluteal pain assessed by a
rheumatologist; b) 26 patients diagnosed with SpA who didn’t have
SJ tenderness and had normal physical examination; c) control group
of 27 subjects (healthy subjetcs or with mechanical lumbar pain).
All patients included that were diagnosed with SpA met almost the
European Spondyloarthropathy Study Group (ESSG) classification
criteria. Physical examination of the SJ included: sacral sulcus
tenderness, iliac gapping, iliac compression, midline sacral thrust
test, Gaenslen’s test, and Patrick s test were used as gold standard.
Both SJ were examined with Doppler ultrasound (General Electric
Logiq 9, Wauwatosa WI, USA) fitted with a 9-14 Mhz lineal probe. The
ultrasonographer was blinded to clinical data.
Doppler in SJ was assessed as positive when both Doppler colour
and resistance index (RI)<0.75 within the SJ area were present.
Statistical analysis was performed estimating sensitivity and specificity
against gold standard. The Kappa correlation coefficient was used for
reliability study.
Results: 106 cases (53 female, 55 male; mean age 36 10 years) were
studied. There were no statistical differences between groups related
to age or sex. Physical examination of SJ was positive in 38 patients
(59 sacroiliac joints). US detected Doppler signal within SJ in 37
patients (58 SJ): 33 of them were symptomatic SpA (52 SJ), one of
them were asymptomatic SpA (1 SJ) and one was a healthy control (1
SJ). The accuracy of US when compared to clinical data as gold
standard at subject level in the overall group was: sensitivity of 68.6%
and specificity of 85.7%, positive predictive value of 70.5% and
negative predictive value of 84.5%. A positive likelihood ratio of 4.8, a
negative likelihood ratio of 0.36 and a kappa coefficient of 0.55 were
achieved.
Conclusions: Doppler US of SJ seems to be a valid method to detect
active SJ inflammation.
Disclosure statement: The authors have declared no conflicts of
interest.
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245. EUROQOL-REPORTED HEALTH DISABILITY
DEMONSTRATES REDUCED QUALITY OF LIFE REMAINING
CONSTANT OVER TIME IN ESTABLISHED PSORIATIC
ARTHRITIS
William Tillett1, Charlotte Cavill2, Ellie Korendowych1 and
Neil McHugh1,3
1Royal National Hospital for Rheumatic Diseases, Bath,
United Kingdom; 2Rheumatology, Bath Institute for Rheumatic
Disease, Bath, United Kingdom; 3Department of Pharmacy and
Bath Pharmacology, University of Bath, Bath, United Kingdom
Background: Psoriasis (PsO) and Psoriatic arthritis (PsA) are known to
have a significantly detrimental effect on health related quality of life
(HRQoL). The EuroQol (EQ5D) has been used in a number of PsA
clinical trials, distinguishes well across levels of PsA severity, and
demonstrates utility gain in patients started on anti-TNF therapy within
the first few weeks, sustained over time. Our objective was to measure
health related quality of life in PsA using the EQ5D and assess change
over time; dependent on age, gender, disease duration and anti-TNF
treatment.
Methods: The EQ5D is a self reported questionnaire describing
health-related quality of life consisting of five descriptive questions
(EQ5D) converted into a single summary index using UK valuation
index and a visual analogue scale (EQ5Dvas) from 100 as best
imaginable health and 0 worst imaginable health. 520 patients were
sent EQ5D questionnaires at six month intervals between 1/2008 and
1/2010. 317 patients returned questionnaires. 287 patients completed
the EQ5D fully on at least one time point. 184 patients completed
EQ5D at two or more time points. HAQ was available for 173 patients
and DLQI for 24 patients. The first and last questionnaires were
compared, mean interval 1.2yrs (443 days, range 4-882). Comparisons
over time were made with paired t test or Wilcoxon rank as
appropriate. Correlations were performed using the Pearson correla-
tion coefficient.
Results: Of the 287 patients the mean age was 66yrs (median 70,
range 20-86), 50.2% male (n¼144) 49.8% female (n¼143) and
disease duration mean 16.9yrs (range 0-57yrs). The mean EQ5Dvas
was 68.1 (Standard Deviation 23, Standard Error of Mean 1.3), male
68.8 (SD 23.4 SEM 1.9), female 67.5 (SD 28.8, SEM 1.9). Results of the
184 patients who completed questionnaires at two time points are
reported in Table 1. HAQ (Minimally Important Difference [MID] 0.22)
and DLQI (MID between 2.2 and 3.1) demonstrated statistical but not
clinically significant improvement. There was no change in EQ5D or
EQ5Dvas over time between age, gender, disease-duration or anti-
TNF treatment. EQ5Dindex demonstrated good correlation with the
HAQ (-0.56) and DLQI (r¼0.59) significant at p<0.01.
Conclusions: Health related quality of life as measured with the EQ5D
and HAQ demonstrates reduced quality of life in PsA patients and this
impairment remains constant over time irrespective of age, gender,
disease-duration or therapy. However, our study will not have
captured early phase improvement following treatment initiation that
we are now studying prospectively.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1. EQ5D, HAQ and DLQI 1.2 year interval (range 4-882 days)
Outcome Mean
baseline
Mean
follow up
Mean
change
SD SEM t Sig
(2tailed)
EQ5Dvas (n¼ 184) 66.3 64.7 1.58 23.79 1.75 0.90 0.36
EQ5Dindex (n¼ 184) 0.60 0.63 0.03 0.27 0.20 1.49 0.13
HAQ (n¼ 173) 1.02 0.92 0.10 0.56 0.04 2.52 0.01
DLQI (n¼ 24) 4.20 2.41 1.79 3.84 0.78 2.2 0.03
Paired t-test
246. EMPLOYMENT STATUS IN A GROUP OF PATIENTS
WITH ANKYLOSING SPONDYLITIS TAKING PART IN
A CLINICAL TRIAL BETWEEN 2004-2006
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Background: Patients with many rheumatological conditions develop
a degree of work disability or even leave employment. In rheumatoid
arthritis a 2.0 to 2.7 fold increased risk of being unable to work has
been reported. In other rheumatological conditions work disability
rates of between 20 and 40% have been reported. In 2008 a UK wide
survey of 612 patients with ankylosing spondylitis (AS) reported that
only 60.7% of working age patients were in employment, approxi-
mately 14% lower than the UK national average at that time. A similar
employment rate was reported in a Dutch study and other groups have
reported figures of between 10 and 40%. The analysis of employment
data has become of more interest recently and is increasingly
considered when treatment and funding decisions are made. We
present the baseline employment statistics of a group of AS patients
recruited to the BIAS (Bisphosphonates in AS) trial between 2004-
2006. This data provides UK employment data just prior to anti-TNF
therapy becoming available nationally in the NHS. The BIAS study
results are awaiting publication.
Methods: 180 patients recruited from 6 UK rheumatology depart-
ments met refined modified New York criteria. There was no upper age
limit but all were >21 years.
Results: 165/180 patients recruited were of working age. 125/165
(76%) were in employment, but only 57.5% were working full time. 33/
165 (20%) were receiving incapacity benefits. 57/165 (40.7%) of those
working had a BASDAI >4 and 37 of those were working full time.
These figures should be compared to the 2004-6 average UK
unemployment rate which was 4.7%.
In those who were in work there was no significant correlation
between hours worked and BASDAI, BASFI, or BASMI scores.
Conclusions: The ability to work for patients with AS is affected at
both an individual and societal level, and should be considered as
integral to decision making at both levels. Epidemiological data, as
reported here, is required to inform such decisions.
These results support previous reports that patients with AS are
less likely to be able to work than the general population. However it is
interesting that unemployment levels in this cohort are lower than
those described only 2 years later in a large UK based epidemiological
survey. This may have been influenced because patients with disability
preventing them from working may also have felt unable to commit to
taking part in a trial. In addition there were low levels of unemployment
in the UK during data collection. In times of increasing unemployment
those with less severe disability might consider taking early retirement
or redundancy if offered. It also gives a snapshot of employment at
a time before anti-TNF alpha therapy was widely available. As
employment data is increasingly considered when treatment and
funding decisions are made it is a helpful addition to the literature
available when considering the impact that new therapies have had.
Disclosure statement: The authors have declared no conflicts of
interest.
247. THE EFFICACY OF ANTI-TNF DRUGS IN A REAL-LIFE
POPULATION WITH ANKYLOSING SPONDYLITIS
IS SUSTAINED FOR UP TO SIX YEARS
Louise Hamilton1, Alan Brooksby1, Jane Leeder1 and Karl Gaffney1
1Rheumatology Department, Norfolk and Norwich
University Hospital, Norwich, United Kingdom
Background: The efficacy of anti-TNF drugs in ankylosing spondylitis
(AS) has been well-established by clinical trials. However, less is
known about their long-term effectiveness in routine clinical care.
Methods: All patients prescribed anti-TNF drugs for AS before
October 2006 were included. Data were obtained from our depart-
ment’s biologics register, supplemented by case note review.
Outcome measures included Bath Ankylosing Spondylitis Disease
Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index
(BASFI) and CRP.
Results: A total of 61 patients were identified, of whom 52 were
currently taking anti-TNF drugs. Three patients (5%) discontinued
because of side effects and 8% because of inefficacy. Seventeen
patients (28%) switched to another anti-TNF drug because of
inefficacy or side effects, with 14 of these (82%) continuing the
second drug in the long-term. Baseline data were available for 46
current patients (83% male, median age 53 years (IQR 42-58), median
disease duration 19 years (IQR 12.75 - 24.5). The outcome measures
at each time point are recorded in Table 1. Mean baseline BASDAI was
6.88 (95% CI 6.47, 7.29), falling to 3.53 (2.86, 4.2) at 1 year and 3.14
(2.52, 3.76) at 4 years. For a subset of patients, data was available for 5
years (mean BASDAI 2.23 (1.48, 2.98); n¼20) and 6 years (mean
BASDAI 2.20 (1.61, 2.79); n¼13) of treatment. A similar trend was
seen in BASFI, with mean baseline 6.67 (6.16, 7.18), reducing to 4.10
(3.34, 4.86) at 1 year, 3.84 (3.11, 4.57) at 4 years and 3.04 (2, 4.08) at 6
years (n¼11). Mean CRP also fell from a baseline value of 24.8 (18.04,
31.56) mg/L to 7.3 (4.96, 9.64) mg/L at 1 year, 7.73 (4.69, 10.77) mg/L
at 4 years and 4.77 (3.25, 6.29) mg/L at 6 years (n¼13).
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Conclusions: Although the greatest improvements in BASDAI, BASFI
and CRP are seen after 1 year of anti-TNF treatment, this response is
sustained for up to 6 years in a real-life population with AS.
Disclosure statement: K.G. has received research support from
Pfizer and honoraria from Abbott and Merck. L.H. has received
research funding from Pfizer, and travel assistance from Pfizer and
Schering-Plough (now MSD). All other authors have declared no
conflicts of interest.
248. SOCIODEMOGRAPHIC DIFFERENCES BETWEEN
PATIENTS WITH PSORIATIC ARTHRITIS: A RHEUMATOLOGY
OUTPATIENT BASED COMPARISON OF INDIAN GUJARATI
AND CAUCASIAN PATIENTS
Aruna S. Malipeddi1, Rebecca Neame1, James Francis1 and
Waji Hassan1
1Department of Rheumatology, University Hospitals of Leicester
NHS Trust, Leicester, United Kingdom
Background: There is a paucity of information regarding whether
ethnicity influences the presentation of psoriatic arthritis (PsA).
Leicester has a large Indian Gujarati population, but little is known
about the epidemiology of PsA in this group. The purpose of this study
was to examine whether sociodemographic factors in this group of
patients differ from those in Caucasian patients.
Methods: 60 Gujarati Indians and 60 Caucasians who were diagnosed
with PsA according to the ACR criteria were recruited consecutively
from the rheumatology outpatient clinic. They were assessed using
a standardized questionnaire comprising of previously validated tools
and a clinical examination was carried out. The following data were
collected: age, gender, alcohol intake, smoking status, pain by visual
analogue scale, disability measured using the Stanford Health
assessment Questionnaire, and occupation and employment.
Participants were also asked about the number of family members
at home, the number of people who help them at home, and the
number of state benefits they were in receipt of.
Results: The mean age of the 2 groups of patients did not differ
(50.7 years for the Gujarati Indians and 50.7 years for the Caucasians).
The Gujarati Indian group comprised of 36 (60%) males and 24 (40%)
females. The Caucasian group comprised of 33 (55%) males and
27 (45%) females. Alcohol consumption was significantly higher in
Caucasians (n¼48, 80.0%) compared to the Gujarati Indians (n¼ 28,
46.7%, p<0.0001). Also significantly more Caucasians (n¼37,
61.7%) were current or previous smokers compared to the Gujarati
Indians (n¼ 17, 28.3%, p¼ 0.0004). The Gujarati Indians had sig-
nificantly more disability, Pain, rate of unemployment and higher
claims for benefits (Table 1).
Conclusions: Gujarati Indian patients with PsA have more disability
and pain, compared to Caucasian patients, despite having more
people at home who help them, and despite having a healthier lifestyle
in terms of alcohol intake and smoking history. This group also has
higher levels of unemployment. There is a suggestion that the Gujarati
Indian patients may be more socially deprived as indicated by fewer
years of formal education and the higher number of social benefits
claimed by this group. These findings need to be confirmed by
community-based studies.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1.
Variable Gujarati
Indians
Caucasians p value (significant
if p< 0.05)
Pain by VAS 51.6 34.9 <0.0001
HAQ score 0.9 0.8 0.039
Number of family members at home 3.0 1.7 0.0001
Number of family members who help 1.0 0.4 0.001
Years of formal education 11.8 17.0 0.749
Number Unemployed 21 10 0.036
Number of state benefits received 1.0 0.6 0.079
249. MODIFICATION OF MINIMAL DISEASE ACTIVITY
SCORE BY REPLACEMENT OF PASI WITH PGA FOR
ADALIMUMAB-TREATED PATIENTS WITH
PSORIATIC ARTHRITIS
Philip Mease1, Michele Olds2, Sonja Kary3 and Hartmut Kupper3
1Swedish Medical Center, University of Washington School of
Medicine, Seattle, WA,USA; 2Abbott, Abbott Park, IL,USA;
3Abbott, Abbott GmbH & Co KG, Ludwigshafen, Germany
Background: A new outcome scoring method for measuring a state
of minimal disease activity (MDA) in various clinical manifestations
of psoriatic arthritis (PsA) has recently been proposed. The Psoriasis
Activity and Severity Index (PASI) or body surface area (BSA) are
among the criteria used in this new MDA method. Independent from
the MDA score, the Physician’s Global Assessment of psoriasis (PGA)
was reported to be a more appropriate measure than the PASI for
patients with mild psoriasis (Ps).
Methods: We compared the performance of the MDA with PASI or
PGA using patient data from a 24-week, randomized, placebo-
controlled trial (ADEPT) of adalimumab (ADA) for the treatment of
active PsA. MDA is defined by achieving 5 of the 7 following criteria:
tender joint count (0-78) 1, swollen joint count (0-76) 1, PASI 1 or
BSA 3%, patient pain on a 0-100-mm visual analog scale (VAS) 15,
Patient’s Global Assessment of disease activity (0-100-mm VAS) 20,
Health Assessment Questionnaire score 0.5, and tender entheseal
points 1.1 Only patients from ADEPT with PsA and active Ps (3%
affected BSA) were included in this post hoc analysis. A heel-limited
enthesitis score (0-4) and PASI 1 were used for calculation of MDA at
week 24. We then replaced the PASI 1 criterion with PGA ‘‘Clear’’
(MDA_mod1) and with PGA ‘‘Clear or Almost Clear’’ (MDA_mod2). The
performance of PASI and PGA in the MDA were compared using
combined data from ADA- and placebo-treated patients using the
kappa coefficient.
Results: Baseline characteristics for MDA score criteria were similar
between the ADA and placebo treatment groups. At week 24, MDA/
MDA_mod1/MDA_mod2 was achieved by 40%/38%/40% of 60
ADA-treated patients and 7%/5%/8% of 60 placebo-treated patients
(P<0.001 for all treatment comparisons). Use of PASI 1 yielded
results similar to those obtained using PGA ‘‘Clear’’ or PGA ‘‘Clear or
Almost Clear’’ at week 24. Kappa coefficients showed that PGA ‘‘Clear
or Almost Clear’’ agreed slightly better with PASI 1 than did PGA
‘‘Clear’’ (Table 1).
Conclusions: A new scoring method to assess Minimal Disease
Activity (MDA) in PsA demonstrated that significantly more adalimu-
mab-treated than placebo-treated patients achieved an MDA state by
week 24 in the ADEPT trial (40% vs. 7%, P< 0.001). Performance of
the new MDA scoring method was not altered when PASI 1 was
replaced with PGA ‘‘Clear’’ or with PGA ‘‘Clear or Almost Clear.’’ More
than one-third of patients with PsA who had both active arthritis and
active Ps achieved MDA after 24 weeks of ADA treatment.
Disclosure statement: S.K. is a contract employee of Abbott. H.K.
and M.O. are employees of Abbott and may own Abbott stock or stock
options. P.M. has received research grants and consultancy fees from,
and is/has been a member of speakers’ bureaus for Abbott, Amgen,
Biogen Idec, Bristol-Myers Squibb, Centocor, Genentech, UCB and
Pfizer, and has received a research grant and consultancy fees from
Roche.
TABLE 1.
PASI 1 PGA
‘‘Clear’’
Observed
Agreement,
%
Kappa PGA ‘‘Clear
or Almost
Clear’’
Observed
Agreement,
%
Kappa
Yes No Yes No
Yes 20 15 87 0.65 34 1 86 0.69
No 0 83 16 67
TABLE 1.
Mean (95%CI) Baseline n¼ 46 1 year 2 years 3 years 4 years n¼ 46 5 years n¼ 20 6 years n¼ 13
BASDAI 6.8 (6.47, 7.29) 3.53 (2.86, 4.2) 3.42 (2.73, 4.11) 3.0 (2.34, 3.66) 3.14 (2.52, 3.76) 2.23 (1.48, 2.98) 2.2 (1.61, 2.79)
BASFI 6.67 (6.16, 7.18) 4.10 (3.34, 4.86) 4.14 (3.36, 4.92) 3.82 (3.06, 4.58) 3.84 (3.11, 4.57) 3.30 (2.20, 4.41) 3.04 (2.0, 4.08)
CRP (mg/L) 24.8 (18.04, 31.56) 7.3 (4.96, 9.64) 8.5 (4.78, 12.22) 6.82 (3.92, 9.72) 7.73 (4.69, 10.77) 4.35 (2.77, 5.93) 4.77 (3.25, 6.29)
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250. REGIONAL AUDIT OF THE USE OF ANTI-TNF AGENTS
FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS
IN RELATION TO NICE GUIDELINES
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Karen Obrenovic5, Ravinder Sandhu5, Jonathan Packham6 and
Nicola Erb5
1Rheumatology, Heart of England NHS Trust, Birmingham,
United Kingdom; 2Rheumatology, Worcestershire Acute NHS Trust,
Worcester, United Kingdom; 3Rheumatology, Derby Hospitals
NHS Foundation Trust, Derby, United Kingdom; 4Rheumatology,
Nottingham University Hospitals NHS Trust, Nottingham,
United Kingdom; 5Rheumatology, Dudley Group of Hospitals
NHS Foundation Trust, Dudley, United Kingdom; 6Rheumatology,
University Hospital of North Staffordshire, Stoke-on-Trent,
United Kingdom
Background: Adalimumab and etanercept are recommended by NICE
(TA 143) as treatment options for adults with severe active ankylosing
spondylitis (AS) provided they fulfill clearly defined clinical criteria.
These treatments should be monitored for continued efficacy by
reassessment at regular predefined intervals. Treatment should only
be continued in the presence of an adequate response as defined in
the NICE guidance. The aim of this regional audit was to assess
compliance with these guidelines in secondary care rheumatology
departments.
Methods: Following a pilot audit at two participating centres,
a proforma questionnaire, BASDAI and spinal VAS was sent to
17 rheumatology centres across the East and West Midlands. Data
was collected prospectively over 4 weeks from patients with AS
attending general or specialised out-patient clinics and retrospectively
in patients treated with anti-TNF but not attending follow up during the
4 week observation period.
Results: 331/416 (80%) of patients meeting the modified New York
criteria for AS were male.
97/238 (41%) of patients recruited prospectively were currently
receiving anti-TNF therapy: 44(45%) adalimumab, 49(51%) etanercept
and 4 (4%) infliximab. 11/238 (5%) of patients had previously received
anti- TNF therapy. 130/238 (55%) of patients had not received anti-
TNF. 58/130 (45%) of these fulfilled NICE BASDAI/painVAS criteria, of
these: 14/58 declined treatment, 11/58 had contraindications, 22/58
were being assessed to start anti-TNF, 10/58 were not treated on
clinician’s judgement and 1/58 had funding problems. Reviewing all
patients on anti-TNF, pre-treatment assessments 12 weeks apart
were documented in 154 (55%) patients on anti-TNF with a further
73 (26%) having these at a 4 week interval. Prior treatment with two
or more NSAIDS had been documented in 249 (89%) patients.
Initial assessments 12 weeks after anti-TNF introduction were
conducted in 162 (58%) patients: 48 (17%) patients had a documented
inadequate response at this initial assessment and of these only 9
(19%) had their treatment discontinued. Regular twelve weekly
disease activity assessments were occurring in 128 (46%) patients.
Conclusions: This audit demonstrates areas of sub-optimal compli-
ance with anti-TNF therapy NICE guidance in AS. In the pre-treatment
assessment for anti-TNF therapy, a significant proportion of patients
were being assessed in accordance with BSR guidance as opposed
to NICE guidance. The proportion of patients being assessed at
12 weeks after treatment initiation was sub-optimal. Less than 20%
of patients with a defined inadequate response at 12 weeks had their
treatment discontinued. Less than half of the patients received regular
12 weekly assessments. Reasons for this lack of compliance require
further evaluation.
Disclosure statement: The authors have declared no conflicts of
interest.
251. INVESTIGATING THE USE OF THE NEW RA
CLASSIFICATION CRITERIA IN PSORIATIC ARTHRITIS
Laura C. Coates1, Philip Conaghan1, Paul Emery1, Michael Green2,
Gamal Ibrahim3, Helen MakIver3 and Philip Helliwell1
1LIMM, Academic Section of MSK Disease, University of Leeds,
Leeds, United Kingdom; 2Rheumatology Department, York Hospitals
NHS Trust, York, United Kingdom; 3Rheumatology Department,
Bradford Hospitals NHS Trust, Bradford, United Kingdom
Background: The new ACR-EULAR classification criteria for rheuma-
toid arthritis (RA) have been developed in undifferentiated arthritis
populations. They state that the criteria should only be applied in
patients with synovitis not better explained by another disease, but do
not state how alternative diagnoses should be excluded. The aim of
this study was to investigate whether the new ACR/EULAR criteria for
early RA are robust in excluding PsA.
Methods: The new ACR/EULAR criteria for early RA and the
Moll&Wright and CASPAR criteria for PsA were applied to cases of
early PsA (less than 24 months symptom duration), early RA and other
forms of early inflammatory arthritis who were all disease-modifying
anti-rheumatic drug naive. Gold standard diagnosis was confirmed by
a consultant rheumatologist. All joints required for the ACR/EULAR
criteria were assessed.
Results: 111 early PsA cases, 82 early RA cases and 29 other early
arthritis controls (undifferentiated arthritis n¼13, spondyloarthritis
n¼ 9, inflamm OA n¼ 4, crystal arthritis n¼3) were recruited. The
sensitivity of the ACR/EULAR criteria (score 6) in classifying early RA
was 91%. The specificity for the criteria when considering all other
diagnoses was 53%. When considering the specificity only for PsA, it
was lower at 48%. When comparing classification criteria for RA and
PsA, none of the RA patients met the PsA criteria (either Moll&Wright
or CASPAR), and only 1 of the other inflammatory arthritis patients
fulfilled these criteria. The majority of PsA patients who met the RA
classification criteria also met the PsA classification criteria (48 of 58).
The 10 patients who met the ACR/EULAR criteria but not the CASPAR
criteria all scored 2 CASPAR points.
Conclusions: The new ACR/EULAR criteria are sensitive at identifying
early RA but are not specific when considering psoriatic arthritis. The
majority of PsA patients met the criteria due to high joint counts
despite negative RF and psoriasis. The ACR/EULAR criteria must be
used with caution in an early arthritis population particularly when
patients have evidence of skin or nail psoriasis.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1.
ACR/EULAR criteria components
fulfilled (% with feature)
Early PsA
(n¼111)
Early RA
(n¼ 82)
Other controls
(n¼ 29)
synovitis of at least 1 joint 92 96 83
1 large joint 46 50 45
2-10 large joints 53 46 28
1-3 small joints 23 11 28
4-10 small joints 41 37 35
>10 joints including 1 small joint 30 60 7
Neg RF and ACPA 94 20 79
low positive RF or ACPA 4 10 14
high positive RF or ACPA 3 71 7
duration over 6 weeks 99 98 83
raised CRP or ESR 48 77 63
252. EPITOPE MAPPING OF A NOVEL B27-SPECIFIC
ANTIBODY
Joanna L. Giles1, Kirsty McHugh1, Katilin DiGleria1, Jackie Shaw1,
Simon Kollnberger1, Katsumi Maenaka2, Osiris Marroquin3,
Christoph Renner3 and Paul Bowness1
1Human Immunology Unit, Weatherall Institute of Molecular
Medicine, Oxford, United Kingdom; 2Laboratory of Biomolecular
Science, Hokkaido University, Hokkaido, Japan; 3Department of
Internal Medicine-Oncolog, University Hospital Zurich Head, Zurich,
Switzerland
Background: The major histocompatibility complex (MHC) allele,
HLA-B27 (B27), is strongly associated with the development of
spondyloarthritis. The classic immunological function of MHC mole-
cules is to present peptides, in a heterotrimeric complex with beta-2-
microglobulin (b2m), to CD8þ T cells. However, B27 has been shown
to form non-classical b2m-free homodimers at the cell surface. It has
been suggested that there may be a pathogenic role for cell surface
B27 homodimer interactions with natural killer (NK) cell receptors, such
as leukocyte immunoglobulin-like receptors (LILRs) and killer immu-
noglobulin-like receptors (KIRs). Here, we have prepared the ground-
work for future investigation of the role of B27 on the cell surface by
measuring the affinity and specificity of a heavy chain specific antibody
(HC-10) and a candidate B27 homodimer-specific monoclonal anti-
body (HD6) to the B27 homodimer.
Methods: 1) B27 was expressed in E.Coli, purified and then refolded
by limiting dilution in presence of peptide. 2) Isolation of refolded
homodimer protein complexes was conducted by gel exclusion
chromatography 3) Surface Plasmon Resonance (SPR) was used to
analyse the binding specificity and affinity of HD6 for B27 homodimer
4) Epitope mapping using Trypsin Digest of B27 and then Mass
spectroscopy was used to identify a possible binding region of HD6 to
the B27 homodimer.
Results: Using SPR, HD6 is shown to bind to the B27 homodimer, but
not to B27 heterotrimers, HLA-A3 heterotrimers or HLA-G homo-
dimers. Furthermore, HD6 is shown to bind with a high affinity to B27
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homodimers, demonstrating a KD of 280 nM. In addition, SPR
competition experiments and Mass Spectroscopy based epitope-
mapping experiments have allowed the development of a model for
HD6 binding to the B27 homodimer.
Conclusions: These findings are important as they improve our
understanding of the specificity and affinity of the HD6 antibody. This
is vital in our assessment of HD6 and its use in in vivo experiments,
and as a potential therapeutic agent.
Disclosure statement: The authors have declared no conflicts of
interest.
253. DISCONNECT BETWEEN DISEASE ACTIVITY AND
JOINT SPACE NARROWING FOR PATIENTS WITH PSORIATIC
ARTHRITIS TREATED WITH ADALIMUMAB PLUS
METHOTREXATE BUT NOT FOR PATIENTS TREATED
WITH METHOTREXATE ALONE
Robert Landewe1, Christopher Ritchlin2, Michele Olds3,
Benoit Gue´rette4 and Frederic Lavie4
1Maastricht University, Medical Center, Maastricht, Netherlands;
2University of Rochester, School of Medicine and Dentistry,
Rochester, NY, USA; 3Abbott, Laboratories, Abbott Park, IL,USA;
4Abbott, France, Rungis, France
Background: Joint space narrowing (JSN) is a critical outcome in
rheumatoid arthritis (RA) because it is more strongly associated with
disability than bone erosions. The relationships between disease
activity, treatment, and JSN have not been fully explored in psoriatic
arthritis (PsA).
Methods: This post hoc analysis explored whether treatment with
adalimumab (ADA), with or without methotrexate (MTX), resulted in
greater inhibition of JSN than placebo (with or without MTX) in PsA
patients. ADEPT was a 24-week, randomized, placebo-controlled trial
of ADA for the treatment of active PsA. Treatment groups were
randomized following stratification of subjects with MTX usage (3
months duration, 50.5% of patients). Time-averaged 28-joint Disease
Activity Scores (TA-DAS28) were calculated at 12 and 24 weeks. JSN
was assessed at week 24. Post hoc analyses evaluated the relation-
ship between TA-DAS28 categories and JSN change (JSN) from
baseline to weeks 12 and 24 in the intention-to-treat population.
Results: Mean overall JSN at week 24 was 0.2 for the ADAMTX
group and 0.4 for the placeboMTX group (P<0.001). Mean JSN
appeared to increase with TA-DAS28 in the placebo group but not the
ADA group (Table 1).
Conclusions: JSN was associated with TA-DAS28 in the
placeboMTX group, but not the ADAMTX group. These data
suggest that ADA may alleviate JSN independent of inflammation,
potentially through inhibition of chondrocytic release of matrix-
degrading substances.
Disclosure statement: B.G., F.L. and M.O. are employees of Abbott
and may own Abbott stock or stock options. R.L. has received
research grants and consultancy fees from, and is/has been a member
of speakers’ bureaus for Abbott, Amgen, Centocor, Pfizer/Wyeth, UCB
and Bristol-Myers Squibb. C.R. has received research grants from
Abbott, Amgen, Pfizer and Centocor, and consultancy fees from
Centocor, Schering-Plough, Bristol-Myers Squibb and Calcimedica.
TABLE 1.
JSNSD (n) TA-DAS28 Category
Week 12 2.6 >2.6-3.2 >3.2-5.1 >5.1
PlaceboMTXa 0.2 1.16 (9) 0.1 0.17 (9) 0.2 0.7 (79) 1.02.52 (52)
ADAMTXa 0.1 0.79 (40) 0.0 0.32 (27) 0.4 1.49 (59) 0.01.01 (15)
P valueb 0.85 0.59 < 0.001 0.02
Week 24
PlaceboMTXa 0.2 0.99 (12) 0.0 0.14 (12) 0.1 0.59 (75) 1.12.58 (50)
ADAMTXa 0.0 0.56 (49) 0.2 1.22 (26) 0.4 1.43 (52) 0.20.9 (14)
P valueb 0.77 0.18 0.001 0.14
aMTX used by subjects with 3 months MTX duration before baseline. bP value
for difference between treatment groups
254. HIGH LEVEL RESPONSES IN PSORIATIC ARTHRITIS
PATIENTS TREATED WITH GOLIMUMAB: RESULTS FROM
WEEK 104 OF THE GO-REVEAL STUDY
A. Kavanaugh1, I. McInnes2, G. G. Krueger3, D. Gladman4,
J. Zrubek5, N. Goldstein5, S. Xu6, S. Mudivarthy6, M. Mack6 and
P. Mease on behalf of the GO-REVEAL Investigators7
1Rheumatology, University of California San Diego, La Jolla, CA,USA;
2Rheumatology, University of Glasgow, Glasgow, United Kingdom;
3Rheumatology, University of Utah Health Sciences, Salt Lake City,
UT, USA; 4Rheumatology, The Toronto Western Hospital, Toronto,
ON, Canada; 5Immunology, Centocor Research & Development, Inc.,
Malvern, PA,USA; 6Biostatistics, Centocor Research & Development,
Inc., Malvern, PA,USA; 7Rheumatology, Swedish Medical Center/
University of Washington, Seattle, WA,USA
Background: The purpose of this study was to assess high level
responses in active psoriatic arthritis pts treated with golimumab
(GLM) through wk104.
Methods: PsA pts with 3 swollen and 3 tender joints and psoriasis
(PsO) were randomized to: subcutaneous (SC) PBO (Grp 1), GLM
50 mg (Grp 2), and GLM 100 mg (Grp 3) q4wks. At wk16, pts with
inadequate response entered early escape (EE). Grp 1 crossed over to
GLM 50 mg at wk24. In open label extension (OLE), pts could be dose-
escalated (DE), from GLM 50 mg to 100 mg. 104wk analyses were
based on observed data and randomized grps; no statistical
comparisons were done. High level responses were assessed using
DAS28 (CRP) score <2.6, PASI90, HAQ<0.5, and proportion of pts
without enthesithis, dactylitis or clearing the target fingernail PsO.
Results: 405 pts were randomized: (Grp 1:113pts, Grp 2:146pts, and
Grp 3:146pts); at wk104, 335pts (88, 118& 129, respectively) continued
treatment. GLM was significantly better than PBO in improving signs
and symptoms and radiographic damage at wk24 as previously
reported. High level responses through wk 104 are summarized in
Table 1. Through wk104, 4.4% (11/248) and 5.3% (12/227) of
GLM50mg and 100 mg pts, respectively, discontinued GLM due to
AEs, and 6.5% (16/248) and 7.9% (18/227) of GLM50mg and 100 mg
pts experienced SAEs. Injection site reactions were mild and occurred
in 7.7% (19/248) and 7.0% (16/227) of GLM50mg and 100 mg pts.
Histoplasmosis was reported in 1 pt (GLM100mg). There were 8
malignancies: 3 GLM 50 mg pts (basal cell, colon, lung small cell), and
5 GLM 100 mg pts (3 basal cell, 1 prostate and 1 small cell lung ca).
1 pt died due to lung ca and 1 due to a climbing accident.
Conclusions: Approximately 50% or more of GLM-treated pts treated
achieved DAS28 remission or high level improvement in PsO (PASI90)
or returned to normal physical function (HAQ0.5) after 2yrs of
treatment. Approximately 25% of pts achieved simultaneous improve-
ments in those three parameters. Enthesithis and dactylitis resolved in
approximately 50% and 80% of pts, respectively. Target nail PsO
cleared in more than 50% of pts. Through wk104, GLM demonstrated
safety profile similar to that observed for other anti-TNF agents.
Disclosure statement: D.G., A.K., G.K., I.M. and P.M. have received
research grants from Centocor Research & Development, Inc. N.G.,
M.M., S.M., S.X. and J.Z. are employees of Centocor Research &
Development, Inc.
TABLE 1.
Group 1* Group 2** Group 3***
Randomized pts 113 146 146
Pts with DAS28<2.6 64.0% (55/86) 64.4% (76/118) 68.0% (87/128)
Pts with PASI90 (among
pts with baseline
PSO3%BSA)
47.7% (42/88) 49.2% (59/120) 51.5% (67/130)
Pts with HAQ 0.5 51.7% (45/87) 59.2% (71/120) 53.9% (69/128)
Pts with DAS28 <2.6 and
PASI90 and HAQ 0.5
23.3% (20/86) 28.0% (33/118) 28.6% (36/126)
Pts with enthesitis (among
pts with enthesitis at
baseline)
56.9% (41/72) 43.0% (37/86) 46.0% (46/100)
Pts with dactylitis (among
pts with dactylitis at
baseline)
7.1% (2/28) 21.4% (9/42) 19.6% (9/46)
Pts with no target finger-
nail PSO (among pts
with fingernail PSO at
baseline)
51.5% (34/66) 56.4% (44/78) 61.7% (58/94)
*includes patients randomized to PBO who switched to GLM 50 mg in EE at
week16 or crossed over at week24 and patients who DE from 50 mg to 100 mg in
OLE (n¼ 26) **includes patients randomized to GLM 50 mg who remained on
50 mg, EE to 100 mg at week16 or who DE from 50 mg to 100 mg (n¼ 28) in OLE
***includes patients randomized to GLM 100 mg
255. ALLELE-SPECIFIC MEASUREMENT OF MHC
PROTEIN TURNOVER IN DENDRITIC CELLS: APPLICATION
TO ANKYLOSING SPONDYLITIS
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Reyna Goodman2, Tim Key2, J S Hill Gaston1, Michael J. Deery3 and
Robert Busch1
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Background: MHC polymorphisms may confer increased suscept-
ibility to autoimmune disease by modulating the intracellular fate
of MHC proteins. One example is the association of ankylosing
spondylitis (AS) with B27 subtypes that exhibit slow folding in the
endoplasmic reticulum and aberrant post-Golgi dimerisation.
However, allele-specific differences in MHC class I protein fate have
been difficult to evaluate in antigen-presenting cells (APCs) from
patients, due to a lack of enabling methodologies.
Methods: Biosynthetic labelling with heavy water (2H2O) and peptide
mass spectrometry can be used to quantify protein synthesis in
immortalised cell lines (De Riva et al., Anal. Biochem., 2010). This
approach was extended here to human peripheral blood monocyte-
derived dendritic cells (MoDC) derived from AS patients or from
B27-matched or B27-negative healthy donors. Monocytes were
differentiated using GMCSF and IL4 and the resultant MoDCs labelled
with 5% 2H2O in media for up to 72 hours. Folded HLA-ABC
molecules were immunoprecipitated, resolved by SDS-PAGE, and
digested with trypsin. HLA class I peptides were identified by LC/MS/
MS analysis and compared to each donor’s HLA genotype. Mass
isotopomer distributions of selected peptides were quantified by LC/
MS before and during 2H2O labelling and used to calculate rates of
fractional protein synthesis and turnover. As an internal control, HLA-
DR molecules were immunoprecipitated and turnover was measured
using a monomorphic DR peptide.
Results: Spontaneous MoDC activation varied with cell density, and
conditions minimising this effect were established. 2H2O labelling did
not activate MoDCs, provided that LPS was excluded. Label
incorporation was detectable in monomorphic and allele-specific
class I-derived peptides, including B27-specific peptides. Turnover
rates of MHC class I molecules in immature MoDC were measured
precisely and, in healthy donors, resembled published turnover rates.
Whereas class I synthesis persisted after LPS treatment, HLA-DR
synthesis and turnover were shut down 24 hours following LPS
stimulation. We are now comparing B27 turnover rates with those of
other class I molecules and examining MHC protein turnover in
patients with AS.
Conclusions: The 2H2O/peptide MS approach permits precise, non-
radioactive quantification of MHC class I protein turnover, including
B27, in small-scale cultures of MoDC. The ability to perform allele-
specific measurements in short-term cultures of antigen-presenting
cells from AS patients will be instrumental in dissecting the impact of
B27 and other disease-related variables on MHC protein turnover.
Disclosure statement: R.B. is a consultant for KineMed, Inc. and
holds stock options. All other authors have declared no conflicts of
interest.
256. MASS SPECTROMETRY-BASED DETECTION AND
QUANTITATION OF PUTATIVE BIOMARKERS FOR
ANKYLOSING SPONDYLITIS
Roman Fischer1,2, Cynthia Wright1, Benedikt Kessler1 and
Paul Bowness2
1Nuffield Department of Clinical Medicine, Centre for Cellular and
Molecular Physiology, Oxford, United Kingdom; 2MRC Human
Immunology Unit, Weatherall Institute for Molecular Medicine,
Oxford, United Kingdom
Background: Ankylosing Spondylitis (AS) is a common, inflammatory
rheumatic disease with a predilection for the axial skeleton, affecting
0.2% of the population. The aetiology of AS is unknown and the
diagnosis and prognosis is challenging. Current diagnostic criteria rely
on a composite of clinical features and sacroiliac joint radiological
changes with a mean time of diagnosis up to 5 years. Our study
focuses on the identification of early biological indicators for AS. We
have carried out a global comparison of proteins in the blood of AS
patients and healthy subjects after depleting the 14 most abundant
proteins from serum pools using an antibody based affinity column
and alternatively biochemical depletion of immunoglobulins and
albumin. The depleted serum was further processed to characterize
proteins, endogenous peptides and small metabolic molecules by
mass spectrometry. The detected compounds were quantified and,
where possible, identified. The initial experiments showed that 44
proteins, 51 endogenous peptides and 42 potential metabolites in
serum from AS patients were regulated as compared with healthy
controls.
Methods: The detection and identification of proteins, peptides or
metabolites in body fluids is complex. The dynamic range of proteins in
serum is 12 orders of magnitude and 12 proteins only represent 95%
of the protein content. We used the Multiple Affinity Removal System
(MARS, Agilent) to deplete the 14 most abundant proteins in human
serum. Proteins were separated from small endogenous peptides
and other small molecules by ultrafiltration (5 kDa MWCO). The flow
through was enriched for organic molecules by C18 purification while
the retentate was digested with trypsin. Both samples were subjected
to a LC-MS/MS workflow (Agilent 6520 Q-Tof with Chip-MS) in
triplicates. The label-free data was analysed using Progenesis LC-MS
software (nonlinear Dynamics). Alternatively we biochemically
depleted serum pools of immunoglobins and albumin and used
Tandem Mass Tags (TMT, Thermo) to differentially label control and
AS serum pools before fractionating the combined peptide samples by
preparative isoelectric focussing and LC-MS/MS analysis.
Results: Both experimental setups led to the identification of proteins
which are regulated in AS patient serum pools. In the label-free
approach, we identified 13 proteins which are regulated in AS patient
serum by at least 2-fold, while the TMT based quantitation of the
serum proteome identified 33 regulated proteins. Furthermore, we
found 51 differentially regulated endogenous peptides and 42 potential
metabolites.
Conclusions: Here we present an approach to assess differences
in patient sera using state-of-the-art proteomic technology. The
discovery of differentially regulated proteomic and metabolic com-
pounds in patient serum by mass spectrometry will provide the
framework for identifying potential biomarker candidates in Ankylosing
Spondylitis.
Disclosure statement: The authors have declared no conflicts of
interest.
257. LOW-DOSE INFLIXIMAB TREATMENT FOR
ANKYLOSING SPONDYLITIS: FIVE YEAR FOLLOW-UP
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Karen S. Mills1, Margaret Somerville1, David G. Scott1 and
Karl Gaffney1
1Rheumatology, Norfolk and Norwich University Hospital, Norwich,
United Kingdom; 2Rheumatology, Wockhardt Hospital, Bangalore,
India
Background: The licensed and recommended dose of infliximab for
the management of Ankylosing Spondylitis (AS) is 5 mg/kg every 6-8
weeks. There is evidence that the lower dose of 3 mg/kg has efficacy in
AS. We previously reported a series of 22 consecutive AS patients
treated between 2002 and 2004 with low dose infliximab at a dose of
3 mg/kg 8 weekly. After 12 months of follow up, 63% (n¼ 14) of these
patients had achieved and maintained a 50% BASDAI response.
We now report the follow up for these patients after a further 5 years.
Methods: The 14 AS patients (having initially fulfilled the New York
criteria) who remained on low dose infliximab continued to be followed
up in a specialised biologic clinic on a routine basis. Data on clinical
assessments, drug treatment, metrology, and laboratory tests were
collated on a departmental database. In the case of loss of efficacy,
the dose of infliximab was increased or the anti TNF agent was
switched, as per departmental protocol. If efficacy was waning before
the time of the next infusion, then the low dose was maintained but
frequency of infusions was increased. Conversely, dosing intervals
were increased for patients who remained in remission. Direct drug
cost savings after using the low dose infliximab regimen were
estimated.
Results: In 2010, 9 of 14 patients are still successfully being treated
with low dose infliximab, at a median frequency of 7 (6-12) weekly
infusions. The median duration of infliximab treatment for these 9
patients is 80 (60-99) months. (1 patient had an 18 month gap in
treatment as he was in remission). 33% are on concomitant DMARDs
and 66% are prescribed as required anti-inflammatory medication.
The median BASDAI for this cohort at last assessment was 1.135 (0-
3.4) and median BASFI 1.29 (0-4.62). Of the other 5 patients, the
median survival on low dose infliximab was 30 months. 2 patients
improved on 5 mg/kg infliximab and the other 3 had a good clinical
response when switched to subcutaneous anti TNF therapy. The cost
of each 100 mg of infliximab was taken as £419.62 (cost as per British
National Formulary, September 2010).The current body weight of the 9
patients was used to estimate doses of infliximab given over the
median treatment period of 80 months. Using the median dosing
frequency of 7 weekly infusions, the cost of infliximab 3 mg/kg for
these 9 patients would be £448, 873.60 over 80 months. This is in
comparison to the cost of giving 5 mg/kg at the licensed dose over the
same period- every 6 weeks-£872, 809.60 or every 8 weeks-
£654,607.20. Therefore, using the median results to estimate, the
low dose infliximab saved the department between £2-400,000 over
the past 5 years.
Conclusions: Of the original cohort of 22 patients treated with low
dose infliximab, 9 (41%) maintained a BASDAI 50 response over 5-8
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years of follow up. Starting at a low dose of infliximab for AS and then
titrating up to the licensed dose, if required, appears to have clinical
efficacy and significant economic benefit.
Disclosure statement: The authors have declared no conflicts of
interest.
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Background: Golimumab (GLM), a new human monoclonal anti-TNFa
antibody demonstrated efficacy in improving articular and dermatolo-
gic manifestation, functional status, and quality of life in pts with
psoriatic arthritis (PsA). The effect of GLM on the progression of
structural damage in PsA pts is being reported now.
Methods: Adult PsA pts with 3 swollen & 3 tender joints were
randomized to receive SC placebo (PBO) or GLM (50 or 100 mg) q4
wks. At wk16, pts with <10% improvement in swollen and tender joint
counts entered early escape (EE) in a double-blinded manner to GLM
50 mg (PBO pts) or GLM 100 mg (GLM 50 mg pts). All pts randomized
to PBO received GLM 50 mg from wk24 through wk52. Radiographs of
the hands and feet were obtained at wk0, wk24, and wk52. Erosions
(ERO) and joint space narrowing (JSN) were evaluated by two
independent readers unaware of treatment and image time sequence
using the van der Heijde-Sharp (vdH-S) method modified for PsA.
Changes from baseline in the modified vdH-S scores were compared
at wk 24 using ANOVA with pts’ baseline MTX usage (Y/N) as a factor
in the model based on the van der Waerden normal score (primary
endpoint). Wk24 comparisons were between GLM grps and the PBO
grp, based on the original randomized grps even for pts who entered
EE at wk16. Missing data was imputed using median change from
baseline in total vdH-S scores of all pts within the same MTX stratum
or by linear extrapolation. Due to lack of adequate control arm,
no statistical comparisons were performed at Wk52.
Results: 405 pts were enrolled. Mean age was 46-48 yrs, median
swollen/tender joint counts were 12-14/22-24, HAQ scores were
1.0-1.1, CRP levels were 0.6 mg/dL, and total vdH-S scores were
9.00-10.50. At wk24, the GLM 50mg treatment grp had significantly
less radiographic damage than PBO, as measured by the mean
change from baseline in total vdH-S score (-0.161.31 vdHS vs
0.271.26 vdHS, respectively). Significantly more GLM -treated pts
(50 mg and 100 mg) had no progression defined as change in total
vdH-S score 0 compared with PBO-treated pts (78.8% and 76.6%
vs 62.7%, respectively). In a subset of pts without ERO or JSN at
baseline, significantly more GLM 50 mg and 100 mg pts maintained an
ERO and JSN free state. GLM 50 mg and 100 mg randomized pts had
less progression at wk52 (mean change from baseline in total vdH-S
score [SD]: 0.22 1.64 and 0.14 1.53, respectively)as com-
pared with pts randomized to PBO (0.221.38) who began treatment
with GLM at wk16/24.
Conclusions: GLM 50mg and 100 mg demonstrated inhibition of
structural damage in pts with active PsA through wk24 with the
maintenance of this benefit through wk52.
Disclosure statement: A.Ba., A.Be, M.R., W.X. and J.Z. are employ-
ees of Centocor Research & Development, Inc. C.C., D.G., A.K., G.K.,
I.M., P.M. and D.V. have received research grants from Centocor
Research & Development, Inc.
259. DIFFERENTIAL RESPONSES TO IL-23 AND ACTIVATED
ALLOGENEIC DENDRITIC CELLS IN PATIENTS WITH
PSORIASIS AND PSORIATIC ARTHRITIS
Carmel B. Stober1, Helen J. Benham1, Jane C. Goodall1 and
J.S. Hill Gaston1
1Department of Medicine, University of Cambridge, Cambridge,
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Background: Psoriasis (Ps) is a common inflammatory disease of the
skin affecting 1-3% of the population, and is complicated in 15-30% of
cases by arthritis (PsA). Genome-wide association studies have
identified the IL-23 subunits, p40 and p19, in addition to the IL-23
receptor, as important genes associated with Ps and PsA. IL-23 aids
the survival and expansion of Th17 cells and induces T cells to release
IL-22. We have recently confirmed that higher proportions of CD4þIL-
17þ and CD4þIL-22þ cells are observed in PBMC derived from
patients with Ps and PsA when compared with healthy donors (HD).
This also corresponded to higher levels of IL-17 and IL-22 cytokine
release.
Methods: PBMC derived from HD, Ps, or PsA were stimulated with
anti-CD3/anti-CD28 human T activator beads in the presence or
absence of 10 ng/ml rhIL-23; supernatants were harvested and
analysed by ELISA for IL-17, IL-22 or IFN-. Alternatively, cells were
stimulated with allogeneic dendritic cells (DC) previously cultured in
either medium alone, or PRR agonists including LPS (TLR4), PIC
(TLR3), PICþCLO (TLR3þ7), or curdlan (dectin-1).
Results: As expected, cells from patients with either Ps or PsA
produced higher levels of both IL-17 and IL-22 when compared to HD
cells. IL-23 potentiated secretion of IL-17 but not IL-22 or IFN-; this
effect was most marked in the Ps and PsA groups. IL-23 release from
DC was reproducibly higher following stimulation with PICþCLO as
compared to ultrapure LPS; nevertheless LPS-activated DC were
potent stimulators of both IL-17 and IL-22 in an allogeneic mixed
lymphocyte reaction, when compared to DC activated with PICþCLO.
Thus stimulation of production of these cytokines did simply not
correlate with IL-23 production by DC.
Conclusions: IL-23 is considered an important therapeutic target in Ps
and PsA. We demonstrate that IL-23 modulates Th17 cytokine
responses in patients with Ps and PsA. In addition IL-17 and IL-22
secretion by T cells could also be up-regulated in an IL-23-
independent fashion. This mechanism requires further investigation
and may reveal additional therapeutic targets.
Disclosure statement: The authors have declared no conflicts of
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260. THE PREVALENCE OF INFLAMMATORY RHEUMATIC
DISORDERS AMONG A COHORT OF HIV-INFECTED
PATIENTS WITH MUSCULOSKELETAL SYMPTOMS:
AN EPIDEMIOLOGICAL STUDY
Kaushik Sanyal1 and Karen Walker-Bone2
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Background: Human Immunodeficiency virus (HIV) is a pandemic with
an estimated 34 million infected worldwide. Since the advent of anti-
retroviral therapies (cART) the prognosis has been transformed
resulting in a growing population of HIV-infected patients. However,
it is increasingly clear that cART is associated with non-AIDS
morbidities. Inflammatory rheumatic diseases have been reported in
HIV-infected patients since 1987 although it is unknown if the virus
increases the risk of these conditions. We undertook an observational
study among a well-characterised cohort of HIV-infected patients
attending one clinic, all assessed by one Consultant according to
standardised classification criteria in order to quantify prevalence and
evaluate impact and response to treatment.
Methods: Between 2005 - 2009, 1600 outpatients were registered in
the database of the Department of HIV/GU Medicine with prevalent
HIV infection at one large Teaching Hospital NHS Trust in the South
East of England. During that period, 295 subjects (18.43%) developed
musculoskeletal symptoms or signs and were all referred to a
specialist HIV Rheumatology service, where they were assessed by
one Rheumatologist. In each case, a history and examination and
relevant investigations were carried out. Here we present a detailed
review of the clinical features of all subjects with possible or probable
inflammatory rheumatic syndromes referent to standardised validated
International classification criteria.
Results: Amongst 295 subjects assessed in the HIV Rheumatology
clinic, 35 (12.2%) fulfilled diagnostic criteria for a diagnosis of an
inflammatory rheumatic syndrome. The most prevalent conditions
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were seronegative oligo- or polyarthritis (with axial involvement,
15 cases, prevalence 5%) (without axial involvement, 8 cases,
2.7%). 8 patients fulfilled criteria for a connective tissue disorder
(2.7%). Three subjects presented with a symmetrical polyarthritis
predominantly affecting hands, feet and knees associated with low
titres of rheumatoid factor and negative anti-CCP antibodies. One
subject had immune reconstitution Adult-Onset Still’s Disease.
Sulphasalazine, hydroxychloroquine and oral prednisolone were
effective in HIV infected patients. Limited experience with methotrex-
ate, mycophenolate mofetil and biologics shows evidence of reason-
able safety and effectiveness.
Conclusions: The number of people with prevalent HIV infection is
growing steadily. As with other studies, we have demonstrated that it
is seronegative spondyloarthopathy and seronegative polyarthritis
(Reiter’s, psoriatic) that predominate in HIV infected patients.
However, we have also seen a low prevalence of rheumatoid arthitis
and some connective tissue disorders. Management with DMARDS
and Biologics is tricky on the background of immunosuppression.
Glucocorticoids can be potentiated significantly by concomitant
Ritonavir, a common component of most cART regimens.
Disclosure statement: The authors have declared no conflicts of
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Background: The classification of psoriatic arthritis (CASPAR) criteria
were derived from a large patient dataset and are valid in classifying
established PsA (sensitivity 91.4%, specificity 98.7%). However in the
original study, only 5% of the cohort had early disease (<12 months
disease duration). The aim of this study was to assess the sensitivity
and specificity of the CASPAR criteria in classifying early PsA and to
compare the results to that of the Moll & Wright criteria.
Methods: The CASPAR criteria were applied to cases of early PsA
(<24 months symptom duration) and controls with other forms of early
inflammatory arthritis who were all disease-modifying anti-rheumatic
drug naive. Gold standard diagnosis was confirmed by a consultant
rheumatologist. Proportions of cases and controls meeting the criteria
were compared using McNemars test. Receiver operator character-
istic (ROC) curve analysis was performed to identify the area under the
curve (AUC) and optimal cut point in the CASPAR criteria for a
diagnosis of early PsA.
Results: 111 early PsA cases and 111 early arthritis controls (RA
n¼ 82, undifferentiated arthritis n¼13, spondyloarthritis n¼9, inflamm
OA n¼4, crystal arthritis n¼3) were recruited. The sensitivity of the
CASPAR criteria (score 3) in classifying early PsA was 87.4%
compared to 80.2% for the Moll and Wright criteria. The specificity
for both was 99.1%, with only 1 control patient fulfilling both criteria.
The AUC for the CASPAR criteria was 0.991 compared to 0.896 for
Moll & Wright. When considering different cut-points for the CASPAR
criteria, the best cut-point for classification remained a score of 3 as
in the original CASPAR analysis. Considering a score of 2 gave a
higher sensitivity of 99.1% but resulted in a drop in specificity to
94.6%.
When considering the individual components of the CASPAR
criteria, 96.4% of cases had current, previous or a family history of
psoriasis with 84% having current psoriasis. Dactylitis and nail
psoriasis were highly discriminatory as only 1 control patient each
had these features. Regression analysis identified that psoriasis and a
negative RF were the most important features to differentiate PsA,
followed by nail psoriasis and the presence of dactylitis.
Conclusions: The CASPAR criteria are more sensitive than the Moll &
Wright criteria in classifying early PsA. Although the sensitivity is
slightly lower than that in established disease, the CASPAR criteria are
valid for use as inclusion criteria for early psoriatic arthritis trials.
Disclosure statement: The authors have declared no conflicts of
interest.
TABLE 1.
CASPAR features of PsA Cases (n¼111) Controls (n¼ 111)
current psoriasis 93 4
previous psoriasis 7 1
family history of psoriasis 20 9
nail psoriasis 42 1
negative RF 107 52
dactylitis 31 1
new bone formation 2 0
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THERAPY AND DISEASE ACTIVITY STATE USING THE
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Background: We previously reported that in the ASSERT and GO-
RAISE studies, BASDAI50 response can be accurately predicted with
a combination of baseline characteristics. This analysis compares the
accuracy of predicted response rates and disease activity as
measured by different assessments, including the ankylosing spondy-
litis disease activity score (ASDAS).
Methods: The ASSERT and GO-RAISE trial data were combined and
baseline characteristics were used to predict the probability for
achieving week 12 ASAS20, BASDAI50 and ASDAS major response
and BASDAI and ASDAS scores at week 12. Univariate analyses
identified baseline predictors for response. Variable associations were
explored using Spearman correlation analysis. A stepwise selection
procedure using logistic regression, ROC and correlation analyses was
used to select a final set of predictors. Logistic regression was used to
calculate the predicted week 12 BASDAI and ASDAS scores and the
probability of week 12 response to anti-TNF or placebo respective to
combined selected predictors at baseline. The accuracy of prediction
between the different assessments was compared using ROC
analyses and R-square.
Results: 479 AS patients (NY modified criteria) treated with anti-TNF
and 156 patients treated with placebo with continued conventional
therapy, with BASDAI and spinal pain assessment 4 were included.
Age (mean 39.5; SD 11.3 yrs), BASFI, (mean 5.4; SD 2.2 cm), Berlin
enthesitis-score (mean 2.4; SD 2.9), therapy (anti-TNF or placebo),
CRP (mean 2.1; SD 2.4 mg/dL) and HLA-B27 genotype [(þ) or (-)] were
retained as final predictors of response. The area under the ROC curve
of the model which included the six selected predictors (log transfer of
CRP values) and interactions between predictors was 0.85, 0.79, and
0.75 and the R-square was 0.43, 0.33, and 0.24 for week 12 ASDAS
major response, BASDAI50 response and ASAS20 response, respec-
tively. This indicates good accuracy for prediction of BASDAI50
and ASDAS major response and fair accuracy for ASAS20 response.
The R-squares of 0.49 and 0.27 for ASDAS and BASDAI scores
respectively, indicate that the week 12 disease activity measured by
ASDAS could be more reliably predicted.
Conclusions: Elevated CRP, lower age, lower enthesitis score, lower
BASFI, and presence of HLA-B27 genotype are associated with a
better treatment response at week 12 in ASSERT and GO-RAISE. The
values of these characteristics at baseline allow calculating the
predicted response rates and future disease activity of an individual
patient. The accuracy of predicting ASDAS and ASDAS response is
good and higher than that of other assessments.
Disclosure statement: J.B., A.D., B.D., P.G., R.I., J.S. and D.V. have
received research grants from Centocor Research & Development, Inc.
B.H. and M.R. are employees of Centocor Research & Development,
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263. EARLY REFERRAL OF ANKYLOSING SPONDYLITIS
PATIENTS: RESULTS OF ONE YEAR OUTCOME OF A
SPECIALIZED EARLY ANKYLOSING SPONDYLITIS CLINIC
Yasser El Miedany1 and Deborah Palmer1
1Rheumatology, Darent Valley Hospital, Dartford, United Kingdom
Background: Objective: Development of a protocol to be applied
through a specialized Early Ankylosing Spondylitis Clinic (EAS clinic)
that is able to discriminate between different categories of Low Back
Pain (LBP) for the sake of shortening the time taken to reach the
correct diagnosis and providing the appropriate treatment.
Methods: 42 patients with possible inflammatory LBP were assessed
over 12 months in a special EAS clinic. The patients’ selection criteria
were: symptoms of inflammatory LBP (>3 months), age <40 years,
insidious onset, morning stiffness >30 min, no improvement with rest
and pain at night with gradual improvement upon getting up or with
exercise. Each patient completed a copy of the multidimensional
PROM questionnaire for spondyloarthritis [1]. Clinical assessment was
carried out for: arthritis, enthesitis, uveitis, dactylitis, nail changes,
psoriasis, inflammatory bowel disease (IBD), response to NSAIDs and
family history for spondyloarthritis. Basic blood testing was carried out
including ESR, CRP and HLA-B27. X-ray was done for every patient to
asses for sacroiliitis (according to modified NY criteria) as well as
spondylitic changes. MRI scan for the dorso-lumbar spine and
sacroiliac joints to assess for active inflammatory changes and the
presence of any other focal pathology was also requested.
Results: The mean age of the whole sample was 32.2 þ/- 3.8 years.
78.6% (33/42 patients) were males with a mean disease duration of
14.4 þ/- 2.2 months (range: 6months-6 years). 28 patients were
diagnosed to have spondyloarthritis (5 Ankylosing spondylitis, 8 IBD,
15 psoriasis). The remaining 14 patients had other causes for LBP (8
with L5/S1 disc bulge, 6 partial sacralization of L5/ mechanical LBP).
18/42 (43%) of the patients had HLA-B27 positive. Chest expansion
mean was 4.1 þ/- 0.2 cm), modified Schober’s test was 15-17.5 (þ/-
0.61 cm). In the AS group of patients ESR and CRP were negative
predictors for MRI findings (p >0.05). HLA-B27 prevalence was higher,
but not significant, in the spondylitis group of patients. Spondylitis and
active sacroiliitis were reported in 18/28 patients MRI scans. Sensitivity
of the referral model was 77.4% whereas specificity was 79.3%
(specificity was higher with image modoality 96.3%).
Conclusions: Application of this model has helped in identifying the
patients suffering from early forms of the disease. Patients with chronic
LBP (>3 m) with the onset of symptoms at an age <45 years should be
proposed to physicians in primary care to screen the patients for
possible axial spondylitis. The likelihood of spondylitis increases if
other screening parameters were present, suggesting that this is a
group of patients who should be referred to the rheumatologists with
higher priority. L5/S1 disc bulges remain a strong differential diagnosis
for sacroiliitis and should be excluded first.
Disclosure statement: The authors have declared no conflicts of
interest.
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Background: Possession of HLA-B27 is strongly associated with
development of the spondyloarthropathies, yet the mechanism by
which HLA-B27 confers this susceptibility is unclear. HLA-B27 forms
both heterotrimers (B27HT) associated with peptide and b2m, and
heavy chain homodimers (B272). It has previously been shown that
B272 can assemble from unstable B27HT undergoing endosomal
recycling from the surface. A pathogenic role for these homodimers
has been proposed. However, determination of the extent, distribution
and triggers of B272 expression have been hampered by the lack of
a specific detection reagent. In order to investigate the role of
homodimers in AS, we generated an antibody to B272 using phage
display technology. Here, the recognition of HLA-B27 by this novel
mAb is characterised.
Methods: Phage display technology was used to generate mono-
clonal antibodies specific for B272. Biotinylated recombinant B27HT
and B272 complexes were used for selection of a phage fAb library.
One selected clone, HD6, was then sub-cloned to generate a chimeric
antibody comprising human fAb2 and murine IgG1 Fc. ELISA was
used to confirm its specificity for B272 complexes. For recognition
of cell-expressed B272, human B cell line transfectants, AS patient
and control PBMCs, and splenocytes isolated from HLA-B27
transgenic rats were used and results analysed by FACS. For further
characterisation of the epitope, transfectants were i) treated with acid,
ii) cultured with HLA-B27 specific or control peptides or iii) treated with
the protease papain prior to FACS analysis.
Results: 1) In ELISA, HD6 specifically recognised recombinant B272
but not HLA-A2, B7 or B27HT. 2) HD6 recognises a novel subset of
B27 molecules on the surface of transfected B cell lines, including
LBL721.220, C1R and T2 transfectants. 3) HD6 surface reactivity
is dependent on level of B27 surface expression and is inhibited by a C-
terminal HA tag. 4) The HD6 epitope is resistant to acid treatment but
sensitive to papain cleavage. 5) Peptide addition abrogates HD6
reactivity at the surface for up to 24 h. 6) HD6 bound in FACS to PBMCs
from AS patients but not controls, and to a number of cell subsets from
splenocytes taken from HLA-B27 transgenic rats but not WT.
Conclusions: HD6 is a novel phage display-derived mAb that
recognises both recombinant B272 and an epitope on the surface
of HLA-B27 transfected cell lines. HD6 stains monocytes from AS
patients, implicating these cells in AS pathogenesis, and a number of
cell subsets including monocytes from HLA-B27 transgenic rats. Our
data suggest that peptide binding is not necessary for expression of
the HD6 epitope, and are consistent with B272 expression and
recognition at the cell surface. HD6 will be a powerful tool to address
the potential pathogenic role of B272 in SpA and may additionally
have therapeutic potential.
Disclosure statement: The authors have declared no conflicts of
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265. CRYOGLOBULINEMIC VASCULITIS SECONDARY
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Background: Chronic Hepatitis C virus (HCV) infection can sometimes
be causative of vasculitis. We assessed the incidence, clinical
spectrum and management of cryoglobulinemic vasculitis (CGV)
secondary to HCV infection in a tertiary teaching hospital.
Methods: We included 246 consecutive patients with chronic HCV
infection admitted to our hospital between 01/01/2004 and 31/12/
2008. In those with cryoglobulinemic vasculitis we assessed the
duration of infection (more or less than 36 months), clinical features,
biologic, immunologic and inflammatory status (estimated GFR -
MDRD, complement level, ESR, CRP), viral load, Histological Activity
Index (HAI) and disease activity (assessed with the Birmingham
Vasculitis Activity Score (VAS) 2003; severe vasculitis was defined as
VAS>12).
Results: Of the 246 chronic HCV infection patients, 16 had CGV; 9 had
a duration of the disease>36 months (mean duration 37.4 months,
SD11, range¼ 7-68 months). Eleven of all the 16 patients had
cutaneous involvement, 12 neurologic involvement, 7 renal dysfunc-
tion, 4 joint involvement and 1 had antiphospholipid syndrome. In 12
(75%) patients ESR was>25 mm/h, 11 (69%) had abnormal levels of
CRP and 6 (38%) had low complement levels. The HAI was> 9 in 12
patients, and the mean VAS2003 was 12 (SD2; range¼6-21) Severe
vasculitis was associated with duration of infection> 36 months
(p¼ .03; r¼ .55), renal involvement (p¼ .036; r¼ .83), lower levels of
complement (p¼ .044; r¼ .78) and viral load<800.000 IU/ml (p¼ .041;
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